CN110522926A - 一种可视化纳米免疫制剂及其制备方法、应用 - Google Patents
一种可视化纳米免疫制剂及其制备方法、应用 Download PDFInfo
- Publication number
- CN110522926A CN110522926A CN201910723330.6A CN201910723330A CN110522926A CN 110522926 A CN110522926 A CN 110522926A CN 201910723330 A CN201910723330 A CN 201910723330A CN 110522926 A CN110522926 A CN 110522926A
- Authority
- CN
- China
- Prior art keywords
- canps
- icg
- nano
- preparation
- visualization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 238000012800 visualization Methods 0.000 title claims abstract description 15
- 239000002105 nanoparticle Substances 0.000 claims abstract description 49
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 23
- 235000010410 calcium alginate Nutrition 0.000 claims abstract description 9
- 239000000648 calcium alginate Substances 0.000 claims abstract description 9
- 229960002681 calcium alginate Drugs 0.000 claims abstract description 9
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 230000001900 immune effect Effects 0.000 claims abstract description 5
- 238000002649 immunization Methods 0.000 claims abstract description 5
- 230000003053 immunization Effects 0.000 claims abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 5
- 238000012360 testing method Methods 0.000 claims abstract description 4
- 239000007864 aqueous solution Substances 0.000 claims description 28
- 238000005119 centrifugation Methods 0.000 claims description 18
- 230000001376 precipitating effect Effects 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 16
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 14
- 102100025172 Calpain-1 catalytic subunit Human genes 0.000 claims description 14
- 101710124171 Calpain-1 catalytic subunit Proteins 0.000 claims description 14
- 235000010413 sodium alginate Nutrition 0.000 claims description 14
- 239000000661 sodium alginate Substances 0.000 claims description 14
- 229940005550 sodium alginate Drugs 0.000 claims description 14
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims description 12
- 229960004657 indocyanine green Drugs 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 238000003384 imaging method Methods 0.000 claims description 9
- 239000001110 calcium chloride Substances 0.000 claims description 8
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 8
- 230000005760 tumorsuppression Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 230000003213 activating effect Effects 0.000 claims description 6
- 239000000017 hydrogel Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 241001474374 Blennius Species 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000006185 dispersion Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 235000013339 cereals Nutrition 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102000008096 B7-H1 Antigen Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010019160 Pancreatin Proteins 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229940055695 pancreatin Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000012638 near-infrared photothermal therapy Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Endocrinology (AREA)
Abstract
本发明涉及生物技术和医药技术领域,提供一种可视化纳米免疫制剂及其制备方法、应用。所述纳米免疫制剂为CANPs‑ICG‑anti‑PD‑L1纳米颗粒,以海藻酸钙纳米颗粒为载体,ICG为成像剂,anti‑PD‑L1为免疫检查点封锁剂,所述纳米免疫制剂形貌均一,分散性好,可对肿瘤进行高效的可视化免疫治疗。
Description
技术领域
本发明涉及生物技术和医药技术领域,尤其是一种可视化纳米免疫制剂及其制备方法、应用。
背景技术
近年来,随着纳米医学技术的发展,纳米技术用于恶性肿瘤的治疗日渐成为人们研究的热点。随着多种肿瘤治疗方法的不断发展,人们发现单一的肿瘤治疗方法效果有限,所以以纳米材料为平台的联合治疗策略成为目前的研究热点之一。最近有研究表明,基于纳米材料的免疫疗法可以产生一系列的免疫反应,从而达到免疫治疗的效果。在众多的纳米材料中,天然高分子材料海藻酸钠具有可生物降解性、良好的生物相容性、良好的凝胶性和成膜性等,以海藻酸钠为原料制备的海藻酸钙基生物医用材料在医药和生物技术领域有着广阔的应用前景。吲哚菁绿(ICG)是一种有效的近红外染料,也是为数不多的被美国FDA批准应用临床的染料。注射入体内后,借助近红外(NIR)光可进行可视化显示。由于近红外光具有较强的穿透能力,在808纳米激光的照射下,甚至能显示组织层下10mm处的吲哚菁绿分布。且近年来,随着纳米技术的不断发展,通过纳米颗粒装载吲哚菁绿已取得一系列重要研究进展,是一项成熟的体内成像的方法。肿瘤微环境诱导肿瘤细胞高表达PD-L1,PD-L1通过与PD-1结合,负性调节T细胞功能,同时抑制细胞因子产生,从而促进肿瘤的免疫逃逸。通过阻断PD-1/PD-L1的结合,可恢复免疫细胞对肿瘤的有效免疫应答。anti-PD-L1免疫检查点封锁剂通过负性调节免疫信号通路,降低肿瘤微环境的免疫抑制,重新激活T细胞活性,将肿瘤细胞识别为“非自身”抗原,并将其与“自身”抗原区分开来,达到利用人体自身免疫系统杀伤肿瘤的目的。
发明内容
本发明的目的在于克服现有技术的不足,提供一种一种可视化纳米免疫制剂及其制备方法与应用。
本发明为解决背景技术中提出的技术问题,采用的技术方案是:一种可视化纳米免疫制剂,为CANPs-ICG-anti-PD-L1纳米颗粒,以海藻酸钙纳米颗粒为载体,吲哚菁绿(ICG)为近红外(NIR)光热治疗剂,anti-PD-L1为免疫检查点封锁剂。
优选的,上述纳米免疫制剂,粒径为70-160nm。
优选的,上述纳米免疫制剂,其中,ICG的载药率为75-85%,PD-L1连接率8%-12%。
本发明的第二个技术方案是上述可视化纳米免疫制剂的制备方法,具体方法步骤如下:
(1)制备海藻酸钙水凝胶纳米颗粒CANPs:配制18-36mM CaCl2水溶液和0.03-0.06%(m/v)海藻酸钠水溶液,取27-29mL海藻酸钠水溶液,快速搅拌,同时逐滴加入1-3mLCaCl2水溶液,快速搅拌一小时,10000转每分钟离心收集沉淀。
(2)制备CANPs-ICG纳米颗粒:取3-5mg吲哚菁绿,溶于5ml 10-20mg/ml的CANPs水溶液中,室温搅拌8-12小时,10000转每分钟离心收集沉淀,水洗2-3次。
(3)制备CANPs-ICG-anti-PD-L1纳米颗粒:活化上述CANPs-ICG纳米颗粒表面的羧基,将50-100微克anti-PD-L1加入到上述CANPs-ICG纳米颗粒溶液中,室温搅拌8-12小时,10000转每分钟离心收集沉淀,水洗2-3次。
本发明的第三个技术方案是纳米免疫制剂在制备肿瘤抑制药物方面的应用。
上述纳米免疫制剂制备的肿瘤抑制药物用于对原位肿瘤的成像和免疫治疗,有效抑制肿瘤。
上述纳米免疫制剂制备的肿瘤抑制药物通过808纳米激光连续照射进行成像,从而达到可视化清除肿瘤细胞的效果。
本发明结构有如下有益效果:
上述纳米免疫制剂,为CANPs-ICG-anti-PD-L1纳米颗粒,形貌均一,分散性好,可进行高效的免疫治疗,从而有效抑制肿瘤生长。
附图说明
图1:制备的CANPs-ICG-anti-PD-L1纳米颗粒的透射电镜图。
图2:制备的CANPs-ICG-anti-PD-L1纳米颗粒的粒径分布。
图3:制备的CANPs-ICG-anti-PD-L1纳米颗粒与对照组分别对B16F10细胞进行处理后的死活细胞染色图。
具体实施方式
为进一步说明本发明,现通过具体实施实例对本发明进行详细阐述。
下述实施例中:
(1)制备海藻酸钙水凝胶纳米颗粒CANPs:配制18-36mM CaCl2水溶液和0.03-0.06%(m/v)海藻酸钠水溶液,取27-29mL海藻酸钠水溶液,快速搅拌,同时逐滴加入1-3mLCaCl2水溶液,快速搅拌一小时,10000转每分钟离心收集沉淀。
(2)制备CANPs-ICG纳米颗粒:取3-5mg吲哚菁绿,溶于5ml 10-20mg/ml的CANPs水溶液中,室温搅拌8-12小时,10000转每分钟离心收集沉淀,水洗2-3次。
(3)制备CANPs-ICG-anti-PD-L1纳米颗粒:活化上述CANPs-ICG纳米颗粒表面的羧基,将50-100微克anti-PD-L1加入到上述CANPs-ICG纳米颗粒溶液中,室温搅拌8-12小时,10000转每分钟离心收集沉淀,水洗2-3次。冷冻干燥得到CANPs-ICG-anti-PD-L1纳米颗粒,重悬于去离子水中保存,粒径为70-160纳米(如图1,图2所示)。
评估本发明制备的纳米材料的成像性能实验技术如下:
将B16F10细胞培养于含有10%的胎牛血清的DMEM中,并放置于恒温37℃,含有5%CO2培养箱中培养。在加入CANPs-ICG-anti-PD-L1纳米颗粒前,细胞(1×105cells/cm2)在6孔的培养板中放置24小时。然后细胞被PBS溶液冲洗3次并放入含有1.5×10-9mol/L CANPs-ICG-anti-PD-L1纳米颗粒的溶液中进行孵育。在不同时间点进行成像,对其进行荧光光谱及显微测量。实验结果显示B16F10细胞与CANPs-ICG-anti-PD-L1纳米颗粒孵育后显示出明显的红色,这一结果说明CANPs-ICG-anti-PD-L1纳米颗粒可以显著的被B16F10细胞摄取并且成像性能良好。
评估本发明制备的纳米免疫抑制剂的体外肿瘤细胞杀伤性能实验技术如下:
将B16F10细胞(5000个/孔)在96孔板中培养24小时,吸出培养液,加入含有0.1-0.2毫克每毫升CANPs-ICG-anti-PD-L1(吲哚菁绿:0.01-0.02毫摩尔每毫升,anti-PD-L1:100-200纳摩尔每升)的培养基,继续孵育6-8小时。随后向每孔中加入200微升的磷酸盐缓冲液,将对照组、单一成像组和经过成像及化疗的B16F10细胞用Hoechast/PI混合荧光染料进行死活细胞染色10分钟。在倒置荧光显微镜下通过观察蓝色荧光(活细胞)和红色荧光(死细胞)的比例来判断肿瘤细胞杀伤效果。结果显示肿瘤细胞死亡率可达到75%-80%(如图3所示)。
评估本发明制备的纳米免疫抑制剂的体内肿瘤细胞杀伤性能实验技术如下:
(1)黑色素肿瘤模型的建立:将B16F10细胞复苏并稳定传代3-4次。取处于对数生长期的细胞,用胰酶消化后制成单细胞悬液(密度为1×106每毫升)。取8周龄左右的C57/B6小鼠30只,用1毫升注射器吸取100-200微升的B16F10细胞悬液,注射入小鼠腹腔右上侧的皮下位置,注入的细胞数量约为2×106。注射完毕后将小鼠置于动物房中饲养。
(2)小鼠分组及不同治疗方式:当B16F10荷瘤小鼠的肿瘤直径达到约4-6毫米的时候,开始进行分组治疗。一共分为3组,每组3只老鼠。具体治疗方案如下:
组一:局部注射磷酸盐缓冲液
组二:局部注射CANPs-ICG纳米粒子
组三:局部注射CANPs-ICG-anti-PD-L1纳米粒子
治疗结束后每天测量小鼠的的体重及肿瘤大小,6-7天后收集淋巴结,用胰酶消化成单个细胞,并用CD80/CD86荧光抗体标记,上流式细胞仪对DCs的含量进行分析。结果显示,组三诱导了高水平的DC成熟(80-90%),肿瘤生长明显低于其他两组,有效抑制肿瘤。
实施例1
(1)制备海藻酸钙水凝胶纳米颗粒CANPs:配制18mM CaCl2水溶液和0.03%(m/v)海藻酸钠水溶液,取27mL海藻酸钠水溶液,快速搅拌,同时逐滴加入1mL CaCl2水溶液,快速搅拌一小时,10000转每分钟离心收集沉淀。
(2)制备CANPs-ICG纳米颗粒:取3mg吲哚菁绿,溶于5ml 10mg/ml的CANPs水溶液中,室温搅拌8小时,10000转每分钟离心收集沉淀,水洗2-3次。
(3)制备CANPs-ICG-anti-PD-L1纳米颗粒:活化上述CANPs-ICG纳米颗粒表面的羧基,将50微克anti-PD-L1加入到上述CANPs-ICG纳米颗粒溶液中,室温搅拌8小时,10000转每分钟离心收集沉淀,水洗2次。得到CANPs-ICG-anti-PD-L1纳米颗粒,重悬于去离子水中保存。
实施例2
(1)制备海藻酸钙水凝胶纳米颗粒CANPs:配制24mM CaCl2水溶液和0.04%(m/v)海藻酸钠水溶液,取28mL海藻酸钠水溶液,快速搅拌,同时逐滴加入2mL CaCl2水溶液,快速搅拌一小时,10000转每分钟离心收集沉淀。
(2)制备CANPs-ICG纳米颗粒:取4mg吲哚菁绿,溶于5ml 15mg/ml的CANPs水溶液中,室温搅拌10小时,10000转每分钟离心收集沉淀,水洗2次。
(3)制备CANPs-ICG-anti-PD-L1纳米颗粒:活化上述CANPs-ICG纳米颗粒表面的羧基,将100微克anti-PD-L1加入到上述CANPs-ICG纳米颗粒溶液中,室温搅拌10小时,10000转每分钟离心收集沉淀,水洗2次。冷冻干燥得到CANPs-ICG-anti-PD-L1纳米颗粒,重悬于去离子水中保存。
实施例3
(1)制备海藻酸钙水凝胶纳米颗粒CANPs:配制36mM CaCl2水溶液和0.06%(m/v)海藻酸钠水溶液,取29mL海藻酸钠水溶液,快速搅拌,同时逐滴加入3mL CaCl2水溶液,快速搅拌一小时,10000转每分钟离心收集沉淀。
(2)制备CANPs-ICG纳米颗粒:取5mg吲哚菁绿,溶于5ml 20mg/ml的CANPs水溶液中,室温搅拌12小时,10000转每分钟离心收集沉淀,水洗3次。
(3)制备CANPs-ICG-anti-PD-L1纳米颗粒:活化上述CANPs-ICG纳米颗粒表面的羧基,将100微克anti-PD-L1加入到上述CANPs-ICG纳米颗粒溶液中,室温搅拌12小时,10000转每分钟离心收集沉淀,水洗3次。冷冻干燥得到CANPs-ICG-anti-PD-L1纳米颗粒,重悬于去离子水中保存。
实施例4
CANPs-ICG-anti-PD-L1纳米粒子的光热性能测试:将B16F10细胞培养于含有10%的胎牛血清的DMEM中,并放置于恒温37℃,含有5%CO2培养箱中培养。在加入不同样品前,细胞(1×105cells/cm2)在6孔的培养板中放置24小时。然后细胞被PBS溶液冲洗3次并放入含有不用样品(水,ICG,CANPs,CANPs-ICG,CANPs-ICG-anti-PD-L1)的水溶液(1毫升)中进行孵育。在不同时间点对不同的样品进行成像,并对其进行荧光光谱及显微测量。实验结果与对照组相比(水,ICG,CANPs,CANPs-ICG)显示B16F10细胞与CANPs-ICG-anti-PD-L1纳米颗粒孵育后显示出更明显的红色,说明ICG被CANPs-ICG-anti-PD-L1包载之后成像性能有一定的提高,更加有利于治疗的进行。
实施例5
检验CANPs-ICG-anti-PD-L1纳米粒子的体外抗肿瘤疗效。将B16F10细胞(5000个/孔)在96孔板中培养24小时,吸出培养液,加入含有0.2毫克每毫升CANPs-ICG-anti-PD-L1(吲哚菁绿:0.02毫摩尔每毫升,anti-PD-L1:200纳摩尔每升)的培养基,继续孵育6-8小时。随后向每孔中加入200微升的磷酸盐缓冲液,将对照组、单一成像组和经过成像及化疗的B16F10细胞用Hoechast/PI混合荧光染料进行死活细胞染色10分钟。在倒置荧光显微镜下通过观察蓝色荧光(活细胞)和红色荧光(死细胞)的比例来判断肿瘤细胞杀伤效果。结果显示肿瘤细胞死亡率可达到77.8%。
实施例6
检验CANPs-ICG-anti-PD-L1纳米粒子的体内抗肿瘤疗效。
(1)黑色素肿瘤模型的建立:将B16F10细胞复苏并稳定传代3次。取处于对数生长期的细胞,用胰酶消化后制成单细胞悬液(密度为1×106每毫升)。取8周龄左右的C57/B6小鼠30只,用1毫升注射器吸取100微升的B16F10细胞悬液,注射入小鼠右腿上侧的皮下位置,注入的细胞数量约为2×106。注射完毕后将小鼠置于动物房中饲养。
(2)小鼠分组及不同治疗方式:当B16F10荷瘤小鼠的肿瘤直径达到约5毫米的时候,开始进行分组治疗。一共分为3组,每组3只老鼠。具体治疗方案如下:
组一:局部注射磷酸盐缓冲液
组二:局部注射CANPs-ICG纳米粒子
组三:局部注射CANPs-ICG-anti-PD-L1纳米粒子
治疗结束后每天测量小鼠的的体重及肿瘤大小,6天后收集淋巴结,用胰酶消化成单个细胞,并用CD80/CD86荧光抗体标记,上流式细胞仪对DCs的含量进行分析。结果显示,组三诱导了高水平的DC成熟(86%),肿瘤生长明显低于其他两组,有效抑制肿瘤。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (7)
1.一种可视化纳米免疫制剂,其特征在于:为CANPs-ICG-anti-PD-L1纳米颗粒,以海藻酸钙纳米颗粒为载体,ICG为成像剂,anti-PD-L1为免疫检查点封锁剂。
2.根据权利要求1所述的纳米免疫制剂,其特征在于:粒径为70-160nm。
3.根据权利要求1所述的纳米免疫制剂,其特征在于:所述ICG载药率为75%-85%,PD-L1连接率为8%-12%。
4.权利要求1所述的可视化纳米免疫制剂的制备方法,其特征在于:具体方法步骤如下:
1)制备海藻酸钙水凝胶纳米颗粒CANPs:配制18-36mM CaCl2水溶液和0.03-0.06%(m/v)海藻酸钠水溶液,取27-29mL海藻酸钠水溶液,快速搅拌,同时逐滴加入1-3mL CaCl2水溶液,快速搅拌,离心收集沉淀;
2)制备CANPs-ICG纳米颗粒:取3-5mg吲哚菁绿,溶于5ml10-20mg/ml的CANPs水溶液中,室温搅拌8-12小时,离心收集沉淀,水洗2-3次;
3)制备CANPs-ICG-anti-PD-L1纳米颗粒:活化上述CANPs-ICG纳米颗粒表面的羧基,将50-100微克anti-PD-L1加入到上述CANPs-ICG纳米颗粒溶液中,室温搅拌8-12小时,10000转每分钟离心收集沉淀,水洗2-3次。
5.根据权利要求1所述的可视化纳米免疫制剂在制备肿瘤抑制药物方面的应用。
6.根据权利要求5所述的可视化纳米免疫制剂在制备肿瘤抑制药物方面的应用,纳米免疫制剂制备的肿瘤抑制药物用于对原位肿瘤的成像和免疫治疗。
7.根据权利要求5所述的可视化纳米免疫制剂在制备肿瘤抑制药物方面的应用,纳米免疫制剂制备的肿瘤抑制药物通过808纳米激光连续照射进行成像。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910723330.6A CN110522926A (zh) | 2019-08-06 | 2019-08-06 | 一种可视化纳米免疫制剂及其制备方法、应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910723330.6A CN110522926A (zh) | 2019-08-06 | 2019-08-06 | 一种可视化纳米免疫制剂及其制备方法、应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110522926A true CN110522926A (zh) | 2019-12-03 |
Family
ID=68660483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910723330.6A Pending CN110522926A (zh) | 2019-08-06 | 2019-08-06 | 一种可视化纳米免疫制剂及其制备方法、应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110522926A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111743855A (zh) * | 2020-03-25 | 2020-10-09 | 天津大学 | 一种类风湿性关节炎治疗凝胶制剂的合成方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101549158A (zh) * | 2009-05-08 | 2009-10-07 | 南开大学 | 一种海藻酸钠肝靶向纳米给药系统及其制备方法 |
US20180185395A1 (en) * | 2015-06-16 | 2018-07-05 | Prism Pharma Co., Ltd. | Anticancer agent |
CN109620816A (zh) * | 2018-11-16 | 2019-04-16 | 天津大学 | 一种纳米免疫制剂及其制备方法与应用 |
-
2019
- 2019-08-06 CN CN201910723330.6A patent/CN110522926A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101549158A (zh) * | 2009-05-08 | 2009-10-07 | 南开大学 | 一种海藻酸钠肝靶向纳米给药系统及其制备方法 |
US20180185395A1 (en) * | 2015-06-16 | 2018-07-05 | Prism Pharma Co., Ltd. | Anticancer agent |
CN109620816A (zh) * | 2018-11-16 | 2019-04-16 | 天津大学 | 一种纳米免疫制剂及其制备方法与应用 |
Non-Patent Citations (3)
Title |
---|
FAKHROSSADAT EMAMI ET AL: "Doxorubicin and Anti-PD-L1 Antibody Conjugated Gold Nanoparticles for Colorectal Cancer Photochemotherapy", 《MOL. PHARMACEUTICS》 * |
吴叶 等: "海藻酸钠纳米粒制备的研究进展", 《材料导报A:综述篇》 * |
杭银辉 等: "诊疗一体的吲哚菁绿纳米药物的研究进展", 《影像研究与医学应用》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111743855A (zh) * | 2020-03-25 | 2020-10-09 | 天津大学 | 一种类风湿性关节炎治疗凝胶制剂的合成方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108543074B (zh) | 一种用于肿瘤治疗的外泌体包裹的纳米载药系统及其制备 | |
CN100577209C (zh) | 一种磁性肿瘤双靶向聚合物纳米胶束及其制备方法 | |
CN110384806A (zh) | 载药聚多巴胺/树状大分子-金纳米颗粒的制备及应用 | |
CN109620816A (zh) | 一种纳米免疫制剂及其制备方法与应用 | |
CN108187046A (zh) | 一种改性透明质酸遮蔽的金属有机框架、纳米粒子、纳米粒子的制备方法及其应用 | |
CN109620956A (zh) | 一种智能巨噬细胞肿瘤靶向治疗系统及其制备方法和应用 | |
CN112007170B (zh) | 免疫佐剂功能化金属有机框架材料及其制备方法与应用 | |
CN107349429A (zh) | 一种核酸适配体‑熊果酸的偶联物无载体自组装纳米粒及其制备和应用 | |
CN115089723B (zh) | 一种谷胱甘肽和过氧化氢敏感的锰基纳米颗粒及其制备方法和应用 | |
CN110522926A (zh) | 一种可视化纳米免疫制剂及其制备方法、应用 | |
CN109674764A (zh) | 一种抗肿瘤磁性载药杂化纳米胶囊及其制备方法 | |
CN104147608B (zh) | 一种聚乙二醇‑叶酸修饰的氨基化锂皂石纳米颗粒及其制备和应用 | |
CN108587998A (zh) | 一种外泌体、外泌体的制备方法及其在制备皮肤浅表性肿瘤的药物中的应用 | |
CN110124035B (zh) | 一种金纳米棒/碳酸钙纳米颗粒材料、其制备方法及应用 | |
CN114225029B (zh) | 一种声敏响应的纳米颗粒及其应用 | |
CN109589402A (zh) | 一种具有靶向光热治疗和可控释药的多重作用纳米材料的制备方法及应用 | |
CN113712937B (zh) | 一种血小板药物递送体系及其制备方法和应用 | |
CN107303388B (zh) | 一种基于近红外染料-透明质酸复合物的诊断治疗制剂 | |
CN115137844A (zh) | 用于肿瘤nir-ii光热-免疫治疗的仿生药物及制备方法和应用 | |
CN108771760A (zh) | 具有近红外光热效应和多模态成像功能的硫化铂蛋白纳米粒及其制备方法和应用 | |
CN110327472B (zh) | 一种多功能靶向超声造影剂及其制备方法 | |
CN106924748A (zh) | 高穿透性肿瘤靶向脂质插件的构建及其促进细胞及细胞膜制剂向肿瘤聚集的作用 | |
CN107384863A (zh) | 荧光和spect/ct双影像功能微球示踪的神经干细胞及应用 | |
CN105535973A (zh) | 用于光声成像和/或光热治疗的磷脂-聚苯胺纳米粒及制备方法 | |
CN113662918B (zh) | 一种pH响应型量子点-聚合物靶向药物载体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191203 |